- ASSOCIATE PROFESSOR Medicine, Pulmonary, Critical Care and Sleep Medicine
American Board of Internal Medicine
MD, Kings College
Internship, Medical Internship
Wayne State University
Fellowship, Research Fellow Medicine
Fellowship, Clinical Pulmonary Fellow
* Mount Sinai Medical Center * (NeuroSurgery)
- Dr. Edward Eden joined the staff of St. Luke’s and Roosevelt Hospitals (SLR) in 1985. In 2003, he was appointed SLR’s Director of Pulmonary, Critical Care and Sleep Medicine, a position he now holds with Mount Sinai Health System. At the James P. Mara Center for Lung Disease, a “Center of Excellence” for alpha-1 antitrypsin and other lung disorders, Dr. Eden is Clinical Director. He is also Director of the Pulmonary Rehabilitation Program and Pulmonary Function Laboratories at Mount Sinai Health System.
Dr. Eden has a strong interest in teaching. He is the director of the Pulmonary, Critical Care and Sleep Medicine training program at Mount Sinai Health System. He also teaches second and third year medical students from Columbia University.
Dr. Eden has served as an expert witness and a claims advisor in local and national cases concerning pulmonary and critical care medicine. He is an impartial specialist in the area of pulmonary medicine for NYS WCB. He has also served as a reviewer for the Office of Professional Medical Conduct NYS.
Best Doctor in New York
Designated Alpha-1 Expert
NY Times Magazine
Best Doctor in New York
Best Doctor in New York
ResearchDr. Edward Eden's research interests include investigation of lung-related illnesses, disorders and treatments. He has served as the principal investigator for various projects, including with the Alpha-1 Foundation on targeted detection of alpha-1 antitrypsis deficiency in patients with COPD, and with the COPD Foundation on a bronchiectasis registry consortium. He was also co-investigator for research of HIV infection in alveolar macrophages, and co-investigator for a study of the national registry of patients with alpha-1 antitrypsin deficiency-related emphysema.
Eden E, Nasmyth PA. The cardiovascular effects of L-Dopa in the pithed rat. Br J Pharmac. 1974;51:473-80..;.
Eden E and Turino GM. Recombinant gamma-interferon augments interleukin-1 from endotoxin-stimulated human alveolar macrophages. Am Rev Resp Dis. 1986;133:455-460..;.
Eden E and Turino GM: Interleukin-1 secretion from alveolar macrophages of patients with AIDS, sarcoidosis and fibrosis. J Clin Immunol. 1986;6:326-333..;.
Eden E and Turino GM: Secretion of interleukin-1/leucocytic pyrogen from endotoxin-stimulated human alveolar macrophages is unaffected by Indomethacin. Immunopharmacology. 1986; 12:81..;.
Eden E and Turino GM: Therapeutic applications to the pulmonary circulation in chronic obstructive pulmonary disease. Seminars in Resp Med. 1986;8:184-194..;.
Huang ZB and Eden E: Effect of bronchoalveolar lavage fluid from patients with sarcoidosis or AIDS on ILIB release from alveolar macrophages. Chest. 1990;98:576..;.
Minutoli R, Brachfeld C and Eden E: Bronchoalveolar lavage via a modified stomach tube in intubated patients with AIDS. Thorax. 1990;45:771-73.;.
Sadaghdar H and Eden E: Kaposi's sarcoma presenting as acute respiratory failure. Chest. 1991;100:858-60..;.
Sadaghdar H, Huang ZB and Eden E: Correlation of bronchoalveolar lavage findings to severity of Pneumocystis carinii pneumonia in AIDS. Evidence for the development of high permeability pulmonary edema. Chest. 1992;102:63-69..;.
Potash MJ, Zeia M, Huang ZB, Pearce TE, Eden E, Gendelman HE and Volsky DJ: Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human HIV-1. Virology. 1992;188:864-68..;.
Huang ZB and Eden E: Effects of corticosteroids on ILIB and TNF release from alveolar macrophages of patients with AIDS and lung disease. Chest. 1993;104:751-55..;.
Pearce TE, Nowakowski M, Eden E, Huang ZB, Steiner P, Shahabuddin M, Potash MJ and Volsky DJ: Uniform detection of HIV-1 in alveolar macrophages in pediatric but not adult AIDS patients. J Leukocyte Biol. 1993;53:722-26..;.
Huang ZB, Potash MJ, Simon M, Shahabuddin M, Chao W, Gendelman HE, Eden E and Volsky DJ: Infection of alveolar macrophages with lymphotropic HIV-1 can be arrested after viral DNA synthesis. J Virol. 1993;67:6893-96..;.
Montgomery BA, Feigal DW, Sattler F, Mason GR, Cantanzarro A, Edison R, Markowitz N, Johnson E, Ogawa S, Rovzar M, Uddem SA, Eden E, Hyslop N, Cheung TW, Kessler H, Mildvan D et al: Aerosolized Pentamidine Aerosol versus Trimethoprim/Sulfamethaxazole for Pneumocystis carini pneumonia in AIDS, a multicenter study. Amer J Respir Crit Care Med. 1995;151:1068-1074..;.
Barker A, Brantly M, Cohen A, Connelly R, Crystal R, Eden E, Stoller JK, Turino GM. Clinical features of Individuals with the PiSZ phenotype of alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med. 1996;154:1718-1725.;.
Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH and Turino GM: Atopy, asthma and emphysema in patients with severe alpha 1-antitrypsin deficiency. Amer J Respir Crit Care Med. 1997;156:68-74..;.
Feldman G, Srivastava P, Eden E, Freiden T. Detention until Cure as a Last Resort: New York City’s experience with civil detention of persistently nonadherent TB patients. Seminars in Respiratory and Critical Care Medicine. 1997;18:493-501..;.
Survival and FEV1 decline in individuals with severe deficiency of alpha-1 antitrypsin. The alpha-1 antitrypsin deficiency Registry study group. Am J Respir Crit Care Med. 1998;158 49-59..;.
Eden E: The Relationship between alpha-1 antitrypsin deficiency and asthma. Respiratory Care. March 3 1998, http://www.medscape.com..;.
Feasibility of a clinical trial of augmentation therapy for alpha (1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 2000;161: 796-801.;.
Eden E, Hammel J, Rouhani F, Brantly ML, Barker AF et al. Asthma Features in Severe alpha 1-antitrypsin Deficiency. Experience of the NHLBI Registry. Chest. 2003;123: 765-771..;.
Member Lung disease Writing Group ATS/ACCP/ERS Joint Statement: Standards for the Diagnosis and Management of Individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:820-896..;.
Thomashefski J, Crystal R, Wiedemann H, Mascha E, Stoller J for the Alpha 1-antitrypsin Deficiency Registry Study Group. The bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency: Findings of the death review committee of the national registry for individuals with severe alpha-1 antitrypsin deficiency. Human Pathology. 2004;35: 1452-1461..;.
Stoller JK, Tomashefski J, Crystal RG, Arroliga A, Strange C, Killian DN, Schlucter MD, Wiedermann HP. For the alpha1-antirtrypsin deficiency registry study group. Mortality in individuals with severe deficiency of alpha1-antitrypsin. Findings from the NHLBI Registry. Chest. 2005;127:1196-1204..;.
Eden E, Strange C, Holladay B, Xie L. Asthma and allergy in alpha-1 antitrypsin deficiency. Respiratory Medicine. 2006;100: 1384-1391..;.
Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma—Results from the ALA-ACRC Low dose Theophylline trial. J Asthma. 2007;44:605-608..;.
Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK. Determinants of airflow obstruction in severe alpha 1-antitrypsin deficiency. Thorax. 2007;62: 806-813. .;.
Shujaat A, Minkin R, Eden E. Review of Cor Pulmonale in COPD. International Journal of COPD. 2007;2:273-282..;.
Chambers EC, Heshka S, Huffaker LY, Xiong Y, Wang J, Eden E, Gallagher D, Pi-Sunyer F X. Truncal adiposity and lung function in older black women. Lung. 2008;186:13-17. .;.
DeMeo D, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Sandhaus SA, Stocks JM, Stoller JK, Strange C, Turino GM, Silverman EK. IL10 polymorphisms are associated with airflow obstruction in severe alpha 1-antitrypsin deficiency. AJRCMB. 2008,38(1):114-2..;.
ElSayegh D, Eden E, Shapiro J. Increasing Severity of Status Asthmaticus in an Urban Medical Intensive Care Unit. J Hospital Medicine. 2008;3:206-11..;.
DeMeo D, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Sandhaus SA, Stocks JM, Stoller JK, Strange C, Turino GM, Silverman EK. Heritability of lung function in severe alpha-1 antitrypsin deficiency. Hum Hered. 2008;67(1):38-45..;.
Eden E and Turino GM. α1-Antitrypsin Deficiency. Lessons from Longevity. Editorial Chest. 2009;135:591-592..;.
Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker A.F., Brantly ML., Eden E, McElvaney N.G., Rennard S.I., Stocks J. M., Stoller J.K., Strange C., Turino G., Sandhaus R.A., Griffith J.L., Silverman E.K. Development of Predictive Models for Airflow Obstruction in Alpha-1 Antitrypsin Deficiency, American Journal of Epidemiology. 2009;170(8):1005-13..;.
Eden E. Diagnosis and Treatment of severe Alpha-1 Antitrypsin deficiency. U.S. Respiratory Disease. 2010;5:24-27.;.
Zuwallack R, De Salvo MC, Kaelin T, Bateman ED, Park CS, Abrahams R, Fakih F, Sachs P, Pudi K, Zhao Y, Wood CC. Combivent Respimat Inhaler Study Group: Efficacy and safety of iptratropium bromide/albuterol delivered by Respimat versus MDI. Respir Med. 2010 Aug;104(8):1179-88. .;.
Khouli, H; Jahnes, K; Shapiro, J; Rose, K; Mathew, J; Gohil, A; Han, Q; Sotelo, A; Jones, J; Aqeel, A; Eden, E; Fried, E. Performance of medical residents in sterile techniques during central vein catheterization: Randomized trial of efficacy of simulation-based training. Chest. doi:10.1378/chest.10-0979..;.
Eden E. Asthma and COPD in Alpha-1 Antitrypsin Deficiency. Evidence for the Dutch Hypothesis. COPD. 2010;5:366-374..;.
Khouli H, Astua A, Dombrowski W, Ahmad F, Homel P, Shapiro J, Singh J, Nallamothu R, Mahbub H, Eden E, Delfiner J. Changes in health-related quality of life and factors predicting long-term outcomes in older adults admitted to intensive care units. Crit Care Med. 2011 Apr;39(4):731-7..;.
Castaldi PJ, Demeo DL, Hersh CP, Lomas DA, Soerheim IC, Gulsvik A, Bakke P, Rennard S, Pare P, Vestbo J; AATGM Investigators; ICGN Investigators, Silverman EK. Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. Thorax. 2011 Oct;66(10):903-9. .;.
Rahaghi F; Sandhaus R; Strange C, Hogarth K, Eden, E, Stocks, J, Krowka, M, Stoller J. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. Journal of COPD. April 2012..;.
Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, McElvaney G, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK, Stockley RA, DeMeo DL. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respiratory Research 2012, 13:16 doi:10.1186/1465-9921-13-16..;.
Khouli H, Eden E, Homel P, Sherrid M. Hemodynamic comparison between right heart catheterization and echocardiography in critically ill patients: A prospective study. The Open Critical Care Journal. 2012;5:1-8..;.
Siedlinski M, Klanderman B, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Demeo DL. Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency. Epigenetics. 2012 Jul 1;7(7)..;.
Grosu, HB, Killam J, Khusainova E, Lozada J ,Needelman A, Eden E. Gene, host and environmental interactions in a 19 year old with severe chronic obstructive lung disease; observations regarding the pathophysiology of airflow obstruction. Interntional Journal of COPD. 2012;7: 383-388..;.
O'Sullivan MM, Brandfield J, Hoskote SS, Segal SN, Chug L, Modrykamien A, Eden E. Environmental improvements brought by the legal interventions in the homes of poorly controlled inner-city adult asthmatic patients: A proof-of-concept study. J Asthma. 2012 Oct 1.;.
Wexelman BA, Eden E, Rose KM. Survey of New York City resident physicians on cause-of-death reporting, 2010. Prev Chronic Dis. 2013;10:120288.;.
Shujaat, A, Shapiro JM, Eden E. Utilization of CT pulmonary angiography in suspected pulmonary embolism in a major urban emergency department. Pulmonary Medicine. 2013;2013:915213. doi: 10.1155/2013/915213. .;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Eden did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.